Posted on 09/06/2021 2:07:09 AM PDT by blueplum
Morbidity and Mortality Weekly Report (MMWR) Weekly / August 6, 2021
To further characterize safety of the vaccine, adverse events after receipt of Pfizer-BioNTech vaccine reported to the Vaccine Adverse Event Reporting System (VAERS) and adverse events and health impact assessments reported in v-safe (a smartphone-based safety surveillance system) were reviewed for U.S. adolescents aged 12–17 years during December 14, 2020–July 16, 2021. As of July 16, 2021, approximately 8.9 million U.S. adolescents aged 12–17 years had received Pfizer-BioNTech vaccine.* VAERS received 9,246 reports after Pfizer-BioNTech vaccination in this age group; 90.7% of these were for nonserious adverse events and 9.3% were for serious adverse events, including myocarditis (4.3%). Approximately 129,000 U.S. adolescents aged 12–17 years enrolled in v-safe after Pfizer-BioNTech vaccination; they reported local (63.4%) and systemic (48.9%) reactions with a frequency similar to that reported in preauthorization clinical trials. Systemic reactions were more common after dose 2. CDC and FDA continue to monitor vaccine safety and provide data to ACIP to guide COVID-19 vaccine recommendations.
(Excerpt) Read more at cdc.gov ...
Overall, 8,383 (90.7%) VAERS reports were for nonserious events, and 863 (9.3%) for serious events, including death; 609 (70.6%) reports of serious events were among males, and median age was 15 years. The most commonly reported conditions and diagnostic findings among reports of serious events were chest pain (56.4%), increased troponin levels (41.7%), myocarditis (40.3%), increased c-reactive protein (30.6%), and negative SARS-CoV-2 test results (29.4%) (Table 2); these findings are consistent with a diagnosis of myocarditis. Myocarditis was listed among 4.3% (397) of all VAERS reports.
CDC reviewed 14 reports of death after vaccination. Among the decedents, four were aged 12–15 years and 10 were aged 16–17 years. All death reports were reviewed by CDC physicians; impressions regarding cause of death were pulmonary embolism (two), suicide (two), intracranial hemorrhage (two), heart failure (one), hemophagocytic lymphohistiocytosis and disseminated Mycobacterium chelonae infection (one), and unknown or pending further records (six).
Review of v-safe Data During December 14, 2020–July 16, 2021, v-safe enrolled 66,350 adolescents aged 16–17 years who received Pfizer-BioNTech vaccine (Table 3). After Pfizer-BioNTech vaccine was authorized for adolescents aged 12–15 years (beginning May 10, 2021), v-safe enrolled 62,709 adolescents in this age group. During the week after receipt of dose 1, local (63.9%) and systemic (48.9%) reactions were commonly reported by adolescents aged 12–15 years; systemic reactions were more common after dose 2 (63.4%) than dose 1 (48.9%). Reporting trends were similar for adolescents aged 16–17 years: systemic reactions were reported among 55.7% after dose 1 and 69.9% after dose 2. For each dose and age group, reactions were reported most frequently the day after vaccination. The most frequently reported reactions for both age groups after either dose were injection site pain, fatigue, headache, and myalgia.
During the week after receipt of dose 2, approximately one third of adolescents in both age groups reported fever. Nearly one quarter of adolescents in both age groups reported they were unable to perform normal daily activities the day after dose 2. Fewer than 1% of adolescents aged 12–17 years required medical care in the week after receipt of either dose; 56 adolescents (0.04%) were hospitalized....
UK vaccine advisory board is not recommending shots for healthy under 18’s.
It's counter productive because the best thing for these kids would be to catch covid and quickly recover to provide robust herd immunity.
The risks of serious complications with permanent and irreversible negative long term side effects are disproportionate to any possible benefit. I am at a loss to discern any positive public health outcome from this
The dosage and protocol should be different for younger age groups. Among healthy people with robust immune responses. (IE: one dose only, or two doses spaced out months apart.The heart inflammation usually follows dose 2.)
Worth noting that even for adults/seniors, the two doses put so close together end up serving as more of a primer. Hence the need for boosters.
Countries like Canada spaced out their 2 doses by up to 4 months and data shows that not only does this approach increase and cement more antibodies — but it may in fact lead to less side effects as well...Resulting in longer term protection with less of an initial punch in the body’s system. Makes sense to me!
Canada I believe is having a less difficult time with Delta variant than us at the moment. But who knows...
I’m iffy on under 18’s and not on board with under 12’s. Mostly because under 12s get the MIS=C, which may mean a different treatment path. (havent seen much on it, tho)
What swings me to the under 18 is an article in WebMd that stated, “Last week, a study published in the preprint server medRxiv found that teens were at significantly greater risk of developing heart inflammation after getting COVID-19 itself than from the vaccine. Researchers looked at heart inflammation rates in about 14,000 teens diagnosed with COVID-19 and in a similar number of vaccinated teens who reported side effects. They found that the risk of heart inflammation was 21 times higher among girls with COVID and about six times higher among boys with COVID compared with the vaccination group.”
so faced with kids, and girls especially, getting myocarditis from covid at a greater rate than background rates or vaccine rates, I’m more pushed towards protection, even if most myo’s self-resolve. It’s generally the boys who develop myocarditis.
I would worry more about the coagulopathies with the teen girls. If they are even looking for ithem.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.